Aprea Therapeutics APRE 深 沪
等待开盘 10-28 09:30:00 美东时间
1.34
-0.060
-4.29%
华盛通- 最 高1.43
- 今 开1.40
- 成交量 18.66万股
- 最 低 1.32
- 昨 收 1.40
- 总市值 780.59万
- 52周最高 5.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.32
- 委 比 93.33%
- 总股本 582.53万
- 历史最高 1062.20
- 量 比 0.61
- 振 幅 7.86%
- 历史最低 1.32
- 每 手 1
- 风险率 0.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aprea Therapeutics Advances ATRN-119 Study for Solid Tumors
Aprea Therapeutics, Inc. (($APRE)) announced an update on their ongoing clinica...
今天 01:27
Aprea To Feature Preliminary Results From ACESOT-1051 Trial Through September 17 In Poster Presentation At AACR-NCI-EORTC
3 out of 4 patients achieved stable disease (per RECIST v1.1) at the 100 mg APR-1051 dose level in heavily pretreated gastrointestinal and gynecologic malignanciesDisease stabilization observed in patients with tumors
10-24 20:35
Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051
<p>Aprea Therapeutics reported early results from its Phase 1 ACESOT-1051 trial, showing that 75% of heavily pretreated gastrointestinal and gynecologic cancer patients achieved stable disease at the 100 mg dose of APR-1051, its WEE1 kinase inhibitor. Disease stabilization was observed in tumors with mutations relevant to WEE1 inhibition, including FBXW7, CCNE1, KRAS G12V, and TP53. Dose escalation continues, with patients now enrolling in the 15...
10-24 12:30
Aprea Therapeutics Shifts Focus to Combination Therapies
Aprea Therapeutics ( ($APRE) ) has shared an announcement. On October 15, 2025,...
10-15 20:27
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
Aprea Therapeutics identified the recommended Phase 2 dose of 1,100 mg once daily for ATRN-119, an oral ATR inhibitor, in the monotherapy arm of its ABOYA-119 Phase 1/2a study for patients with advanced solid tumors. The company is pausing further enrollment in monotherapy arms to focus on strategic high-value combinations, such as DNA-damaging agents and immune checkpoint inhibitors, based on preclinical data suggesting synergistic anti-tumor ef...
10-15 12:00
Aprea Therapeutics Announces Two Abstracts On Clinical Programs, APR-1051 And ATRN-119, Accepted For Poster Presentation At EORTC-NCI-AACR International Conference
Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to
10-14 20:03
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
Aprea Therapeutics announced that two abstracts for its clinical programs, APR-1051 and ATRN-119, have been accepted for poster presentations at the EORTC-NCI-AACR conference in Boston. Both presentations will occur on October 24th during Poster Session B in Exhibit Hall D. APR-1051 is a WEE1 inhibitor targeting cancer-associated gene alterations, while ATRN-119 is an ATR inhibitor for advanced solid tumors with DNA damage. The posters will be av...
10-14 12:00
Aprea Therapeutics Highlights Progress in Clinical Trials
Aprea Therapeutics ( ($APRE) ) has provided an announcement. On September 8, 20...
09-08 20:22
Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference
Aprea Therapeutics announced that its management will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 3:30 PM ET in New York. The presentation will focus on Aprea’s innovative cancer treatments targeting specific cancer cell vulnerabilities while sparing healthy cells. Aprea’s lead programs include APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both in clinical development for s...
08-28 12:30
Aprea Therapeutics GAAP EPS of -$0.53
Aprea Therapeutics press release (NASDAQ:APRE): Q2 GAAP EPS of -$0.53. $16.5 million in cash and cash equivalents as of June 30, 2025 More on Aprea Therapeutics Seeking Alpha’s Quant Rating on Aprea T...
08-12 20:14
